Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus ...

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

Angitia Biopharmaceuticals Announces Dosing of First Participant in Phase 2 IDUN Trial of AGA2115 for the Treatment of Osteogenesis Imperfecta

Phase 2 trial of adults with Osteogenesis Imperfecta (OI) is enrolling patients in the US and EUWESTLAKE VILLAGE, Calif., ...
Lupus Foundation of America

Phase 2b JASMINE trial of nipocalimab demonstrates positive results for treatment of systemic lupus erythematosus

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
Business Wire

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety ...
Ophthalmology Times

First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial

SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...
GlobalData on MSN

HUTCHMED begins Phase III segment of metastatic PDAC treatment trial

HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...